Overview

The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes

Status:
Completed

Trial end date:
2016-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if the drug Alpha-1 Antitrypsin (AAT, Aralast NP) will preserve beta-cell function and help slow the progression of type 1 diabetes.

Phase:

Phase 1

Details

Lead Sponsor:

University of Colorado, Denver

Collaborator:

Omni Bio Pharmaceutical, Inc.

Treatments:

Alpha 1-Antitrypsin
Protein C Inhibitor